These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32273232)

  • 1. Autologous bone marrow mesenchymal stromal cell therapy for "no-option" critical limb ischemia is limited by karyotype abnormalities.
    Mohamed SA; Howard L; McInerney V; Hayat A; Krawczyk J; Naughton S; Finnerty A; Holohan M; Duffy A; Moloney T; Kavanagh E; Burke P; Liew A; Tubassam M; Walsh SR; O'Brien T
    Cytotherapy; 2020 Jun; 22(6):313-321. PubMed ID: 32273232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marrow changes and reduced proliferative capacity of mesenchymal stromal cells from patients with "no-option" critical limb ischemia; observations on feasibility of the autologous approach from a clinical trial.
    Mohamed SA; Duffy A; McInerney V; Krawczyk J; Hayat A; Naughton S; Finnerty A; Holohan M; Liew A; Tubassam M; Walsh SR; O'Brien T; Howard L
    Cytotherapy; 2022 Dec; 24(12):1259-1267. PubMed ID: 35999133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients.
    Abdul Wahid SF; Ismail NA; Wan Jamaludin WF; Muhamad NA; Abdul Hamid MKA; Harunarashid H; Lai NM
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010747. PubMed ID: 30155883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and design of the SAIL trial for intramuscular injection of allogeneic mesenchymal stromal cells in no-option critical limb ischemia.
    Wijnand JGJ; Teraa M; Gremmels H; van Rhijn-Brouwer FCC; de Borst GJ; Verhaar MC;
    J Vasc Surg; 2018 Feb; 67(2):656-661. PubMed ID: 29242062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expansion and angiogenic potential of mesenchymal stem cells from patients with critical limb ischemia.
    Brewster L; Robinson S; Wang R; Griffiths S; Li H; Peister A; Copland I; McDevitt T
    J Vasc Surg; 2017 Mar; 65(3):826-838.e1. PubMed ID: 26921003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of the Clinical and Histologic Analysis of Mesenchymal Stromal Cells in AmPutations (CHAMP) trial investigating the therapeutic mechanism of mesenchymal stromal cells in the treatment of critical limb ischemia.
    Wang SK; Green LA; Drucker NA; Motaganahalli RL; Fajardo A; Murphy MP
    J Vasc Surg; 2018 Jul; 68(1):176-181.e1. PubMed ID: 29395424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of mouse bone marrow and adipose tissue mesenchymal stem cells for critical limb ischemia cell therapy.
    Nammian P; Asadi-Yousefabad SL; Daneshi S; Sheikhha MH; Tabei SMB; Razban V
    Stem Cell Res Ther; 2021 Jan; 12(1):58. PubMed ID: 33436054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of the MarrowStim PAD Kit for the Treatment of Critical Limb Ischemia in Subjects with Severe Peripheral Arterial Disease (MOBILE) trial investigating autologous bone marrow cell therapy for critical limb ischemia.
    Wang SK; Green LA; Motaganahalli RL; Wilson MG; Fajardo A; Murphy MP
    J Vasc Surg; 2017 Jun; 65(6):1850-1857.e2. PubMed ID: 28390770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neovascularization capacity of mesenchymal stromal cells from critical limb ischemia patients is equivalent to healthy controls.
    Gremmels H; Teraa M; Quax PH; den Ouden K; Fledderus JO; Verhaar MC
    Mol Ther; 2014 Nov; 22(11):1960-70. PubMed ID: 25174586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of responders to autologous bone marrow cell therapy for no-option critical limb ischemia.
    Madaric J; Klepanec A; Valachovicova M; Mistrik M; Bucova M; Olejarova I; Necpal R; Madaricova T; Paulis L; Vulev I
    Stem Cell Res Ther; 2016 Aug; 7(1):116. PubMed ID: 27530339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous bone marrow cell transplantation increases leg perfusion and reduces amputations in patients with advanced critical limb ischemia due to peripheral artery disease.
    Amann B; Luedemann C; Ratei R; Schmidt-Lucke JA
    Cell Transplant; 2009; 18(3):371-80. PubMed ID: 19500466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia.
    Powell RJ; Comerota AJ; Berceli SA; Guzman R; Henry TD; Tzeng E; Velazquez O; Marston WA; Bartel RL; Longcore A; Stern T; Watling S
    J Vasc Surg; 2011 Oct; 54(4):1032-41. PubMed ID: 21684715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of Adult Human Bone Marrow-Derived, Cultured, Pooled, Allogeneic Mesenchymal Stromal Cells in Critical Limb Ischemia Due to Buerger's Disease: Phase II Study Report Suggests Clinical Efficacy.
    Gupta PK; Krishna M; Chullikana A; Desai S; Murugesan R; Dutta S; Sarkar U; Raju R; Dhar A; Parakh R; Jeyaseelan L; Viswanathan P; Vellotare PK; Seetharam RN; Thej C; Rengasamy M; Balasubramanian S; Majumdar AS
    Stem Cells Transl Med; 2017 Mar; 6(3):689-699. PubMed ID: 28297569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial: the use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia.
    Bura A; Planat-Benard V; Bourin P; Silvestre JS; Gross F; Grolleau JL; Saint-Lebese B; Peyrafitte JA; Fleury S; Gadelorge M; Taurand M; Dupuis-Coronas S; Leobon B; Casteilla L
    Cytotherapy; 2014 Feb; 16(2):245-57. PubMed ID: 24438903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Report of a phase 1 clinical trial for safety assessment of human placental mesenchymal stem cells therapy in patients with critical limb ischemia (CLI).
    Shirbaghaee Z; Heidari Keshel S; Rasouli M; Valizadeh M; Hashemi Nazari SS; Hassani M; Soleimani M
    Stem Cell Res Ther; 2023 Jul; 14(1):174. PubMed ID: 37408043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethnic minorities with critical limb ischemia derive equal amputation risk reduction from autologous cell therapy compared with whites.
    Wang SK; Green LA; Gutwein AR; Drucker NA; Babbey CM; Gupta AK; Fajardo A; Motaganahalli RL; Wilson MG; Murphy MP
    J Vasc Surg; 2018 Aug; 68(2):560-566. PubMed ID: 29503004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo efficacy of endothelial growth medium stimulated mesenchymal stem cells derived from patients with critical limb ischemia.
    Al-Rifai R; Nguyen P; Bouland N; Terryn C; Kanagaratnam L; Poitevin G; François C; Boisson-Vidal C; Sevestre MA; Tournois C
    J Transl Med; 2019 Aug; 17(1):261. PubMed ID: 31399109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell therapy in critical limb ischemia: A comprehensive analysis of two cell therapy products.
    Tournois C; Pignon B; Sevestre MA; Al-Rifai R; Creuza V; Poitevin G; François C; Nguyen P
    Cytotherapy; 2017 Feb; 19(2):299-310. PubMed ID: 27914820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Repeated Bone Marrow Mononuclear Cell Therapy in Patients with Critical Limb Ischemia in a Pilot Randomized Controlled Trial.
    Molavi B; Zafarghandi MR; Aminizadeh E; Hosseini SE; Mirzayi H; Arab L; Baharvand H; Aghdami N
    Arch Iran Med; 2016 Jun; 19(6):388-96. PubMed ID: 27293053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic Mesenchymal Stromal Cells (MSCs) are of Comparable Efficacy to Syngeneic MSCs for Therapeutic Revascularization in C57BKSdb/db Mice Despite the Induction of Alloantibody.
    Liew A; Baustian C; Thomas D; Vaughan E; Sanz-Nogués C; Creane M; Chen X; Alagesan S; Owens P; Horan J; Dockery P; Griffin MD; Duffy A; O'Brien T
    Cell Transplant; 2018 Aug; 27(8):1210-1221. PubMed ID: 30016879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.